dripdd
2021-05-04
still can enter?
After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":106219086,"tweetId":"106219086","gmtCreate":1620122180545,"gmtModify":1634207656811,"author":{"id":3574719738695807,"idStr":"3574719738695807","authorId":3574719738695807,"authorIdStr":"3574719738695807","name":"dripdd","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>still can enter?</p></body></html>","htmlText":"<html><head></head><body><p>still can enter?</p></body></html>","text":"still can enter?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/106219086","repostId":1157490418,"repostType":4,"repost":{"id":"1157490418","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620120727,"share":"https://www.laohu8.com/m/news/1157490418?lang=&edition=full","pubTime":"2021-05-04 17:32","market":"us","language":"en","title":"After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1157490418","media":"Tiger Newspress","summary":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares ","content":"<p style=\"text-align:left;\">(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><b>What happened</b></p><p>Shares of <b>Ocugen</b>(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.</p><p><b>So what</b></p><p>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.</p><p>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"</p><p><b>Now what</b></p><p>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter surging nearly 24% yesterday, OCGN dipped 4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-04 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p style=\"text-align:left;\">(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><b>What happened</b></p><p>Shares of <b>Ocugen</b>(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.</p><p><b>So what</b></p><p>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.</p><p>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"</p><p><b>Now what</b></p><p>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157490418","content_text":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares of Ocugen(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.So whatResearchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"Now whatMusunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.","news_type":1},"isVote":1,"tweetType":1,"viewCount":487,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/106219086"}
精彩评论